Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis

Journal of Rheumatology

Volumn 34, Issue 5, 2007, Pages 1178-1183

  Bansback, Nick ^a   Maetzel, Andreas ^b,c   Drummond, Mike ^d   Anis, Aslam ^e,f   Marra, Carlo ^e   Conway, Peter ^g   Boers, Maarten ^h   Tugwell, Peter ⁱ   Boonen, Annelies ^j  

^a ST PAUL S HOSPITAL   (Canada)

^b AMGEN INC   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF YORK   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^g PFIZER INC   (United States)

^h VU UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Ankylosing spondylitis; Cost effectiveness; Economics

Indexed keywords

ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DISEASE COURSE; ECONOMIC EVALUATION; HEALTH STATUS; HUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; POPULATION; PRIORITY JOURNAL;

COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; EVALUATION STUDIES; HEALTH CARE RATIONING; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; OUTCOME ASSESSMENT (HEALTH CARE); REFERENCE STANDARDS; SPONDYLITIS, ANKYLOSING;

EID: 34248630485     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (49)

1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002;61 Suppl 3:iii8-18.
2. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001;60:353-8.
3. Dagfinrud H, Mengshoel AM, Hagen KB, Loge JH, Kvien TK. Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis 2004;63:1605-10.
4. Ozgul A, Peker F, Taskaynatan MA, Tan AK, Dincer K, Kalyon TA. Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin Rheumatol 2006;25:168-74. Epub 2005 Aug 10.
5. Gran JT, Husby G. Epidemiology of ankylosing spondylitis. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman MH, editors. Rheumatology. 3rd ed. New York: Mosby; 2003.
6. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. J Rheumatol 2000;27:613-22.
7. Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. Rheumatology Oxford 2004;43:1072-84.
8. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
9. Boonen A, van der Heijde D, Landewe R, et al. Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 2003;62:732-40.
10. Van Tubergen A, Boonen A, Landewe R, et al. Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2002;47:459-67.
11. Jansen JP, Hunsche E, Choy E, et al. Economic evaluation of etoricoxib versus non-selective NSAID in the treatment of ankylosing spondylitis in the UK [abstract]. Ann Rheum Dis 2005;64 Suppl 3:1310.
12. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology Oxford 2004;43:1158-66.
13. Kobelt G, Andlin-Sobocki P, Maksymowych W. Cost-effectiveness of infliximab for ankylosing spondylitis in Canada [abstract]. Ann Rheum Dis 2005;64 Suppl 3:406.
14. Boonen A, van der Heijde D, Severens J, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006;65:201-8. Epub 2005 Jul 13.
15. Singh G, Tandon N, Bala M. A cost efficacy analysis on anti-TNF therapy in ankylosing spondylitis [abstract]. Ann Rheum Dis 2005;64 Suppl 3:395.
16. Duff SB, Yeh Y, Yu EB, Woolley JM. The economic impact of etanercept and infliximab treatment in ankylosing spondylitis [abstract]. Ann Rheum Dis 2005;64 Suppl 3:400.
17. Singh G, Tandon N, Bala M. A cost efficacy analysis on anti-TNF therapy in ankylosing spondylitis [abstract]. Arthritis Rheum 2004;Suppl 50:S613.
18. Sculpher MJ, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ 2006;15:677-87.
19. Drummond M, Sculpher MJ. Common methodological flaws in economic evaluations. Med Care 2005;43 Suppl:5-14.
20. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8:iii-iv, ix-xi, 1-158.
21. Coyle D, Tosteson AN. Towards a reference case for economic evaluation of osteoporosis treatments. J Rheumatol 2003;30 Suppl 68:31-6.
22. Maetzel A, Tugwell P, Boers M, et al; OMERACT 6 Economics Research Group. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
23. Gabriel SE, Tugwell P, Drummond M. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. Ann Rheum Dis 2002;61:370-3.
24. Gold MR, Russell LB, Siegel JE, Weinstein MC. Cost-effectiveness in health and medicine. Oxford, UK: Oxford University Press; 1996.
25. Bansback N, Anis A, Boers M, et al. A review of economic evaluations in ankylosing spondylitis: considerations and proposal for an OMERACT reference case [abstract]. Ann Rheum Dis 2006;65 Suppl 11:275.
26. Keat A, Barkham N, Bhalla A, et al. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology Oxford 2005;44:939-47.
27. Pham T, van der Heijde D, Calin A, et al; ASAS Working Group. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum Dis 2003;62:812-6.
28. Landewe R, Rump B, van der Heijde D, van der Linden S. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann Rheum Dis 2004;63:530-4.
29. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
30. Bansback NJ, Regier DA, Ara R, et al. An overview of economic evaluations for drugs used in rheumatoid arthritis: focus on tumour necrosis factor-alpha antagonists. Drugs 2005;65:473-96.
31. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003;326:472.
32. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med 2003;22:3687-709.
33. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
34. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology Oxford 1999;38:878-82.
35. Barkham N, Kong KO, Tennant A, et al. The unmet need for antitumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology Oxford 2005;44:1277-81.
36. Ward MM. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999;12:247-55.
37. Boonen A, van der Heijde D, Landewe R, et al. The SF-6D differentiates less in the lower ranges of the patient's utility when compared with the EQ-5D but has a better reliability and sensitivity to change. Ann Rheum Dis 2007;E-pub.
38. Boonen A, van der Heijde D, Landewe R, et al. Costs of ankylosing spondylitis in three European countries: the patient's perspective. Ann Rheum Dis 2003;62:741-7.
39. Merkesdal S, Ruof J, Huelsemann JL, et al. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis. J Rheumatol 2001;28:657-61.
40. Listing J, Brandt J, Rudwaleit M, Zink A, Sieper J, Braun J. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004;63:1670-2.
41. Boonen A, van der Heijde D, Landewe R, et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
42. Dagfinrud H, Kvien TK, Hagen KB. The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol 2005;32:1899-906.
43. Braun J, Pincus T. Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002;20 Suppl 28:S16-22.
44. Wanders A, Heijde D, Landewe R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
45. Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty - when is there sufficient evidence? Value Health 2005;8:433-46.
46. Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005;14:339-47.
47. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making 1998;18:95-109.
48. Hill S. Transparency in economic evaluations. Pharmacoeconomics 2005;23:967-9.
49. Merkesdal S, Zeidler H. TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue? Curr Rheumatol Rep 2005;7:254-8.